|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCL21 |
Gene summary for CCL21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCL21 | Gene ID | 6366 |
| Gene name | C-C motif chemokine ligand 21 | |
| Gene Alias | 6Ckine | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O00585 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6366 | CCL21 | C04 | Human | Oral cavity | OSCC | 2.83e-05 | 4.77e-01 | 0.2633 |
| 6366 | CCL21 | C30 | Human | Oral cavity | OSCC | 4.20e-09 | 3.43e-01 | 0.3055 |
| 6366 | CCL21 | LP15 | Human | Oral cavity | LP | 4.72e-07 | 1.55e+00 | 0.2174 |
| 6366 | CCL21 | LP16 | Human | Oral cavity | LP | 5.87e-05 | 1.42e+00 | 0.1055 |
| 6366 | CCL21 | LP17 | Human | Oral cavity | LP | 1.79e-06 | 1.04e+00 | 0.2349 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
| GO:003133420 | Oral cavity | OSCC | positive regulation of protein-containing complex assembly | 153/7305 | 237/18723 | 1.18e-15 | 8.33e-14 | 153 |
| GO:004312218 | Oral cavity | OSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 155/7305 | 249/18723 | 7.79e-14 | 4.14e-12 | 155 |
| GO:004312310 | Oral cavity | OSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 122/7305 | 186/18723 | 1.68e-13 | 8.52e-12 | 122 |
| GO:000724910 | Oral cavity | OSCC | I-kappaB kinase/NF-kappaB signaling | 169/7305 | 281/18723 | 4.69e-13 | 2.25e-11 | 169 |
| GO:190290520 | Oral cavity | OSCC | positive regulation of supramolecular fiber organization | 131/7305 | 209/18723 | 3.18e-12 | 1.27e-10 | 131 |
| GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
| GO:005149518 | Oral cavity | OSCC | positive regulation of cytoskeleton organization | 135/7305 | 226/18723 | 1.98e-10 | 5.66e-09 | 135 |
| GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
| GO:005123518 | Oral cavity | OSCC | maintenance of location | 182/7305 | 327/18723 | 6.16e-10 | 1.58e-08 | 182 |
| GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
| GO:003227319 | Oral cavity | OSCC | positive regulation of protein polymerization | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
| GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
| GO:003227120 | Oral cavity | OSCC | regulation of protein polymerization | 134/7305 | 233/18723 | 7.20e-09 | 1.51e-07 | 134 |
| GO:003461218 | Oral cavity | OSCC | response to tumor necrosis factor | 143/7305 | 253/18723 | 1.09e-08 | 2.23e-07 | 143 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:190165419 | Oral cavity | OSCC | response to ketone | 114/7305 | 194/18723 | 1.82e-08 | 3.60e-07 | 114 |
| GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
| GO:003158917 | Oral cavity | OSCC | cell-substrate adhesion | 193/7305 | 363/18723 | 2.48e-08 | 4.82e-07 | 193 |
| GO:001081019 | Oral cavity | OSCC | regulation of cell-substrate adhesion | 126/7305 | 221/18723 | 4.02e-08 | 7.55e-07 | 126 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa040644 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
| hsa0406411 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Breast | ADJ |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Breast | Healthy |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Breast | IDC |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Breast | Precancer |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Endometrium | ADJ |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Endometrium | AEH |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Endometrium | EEC |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Endometrium | Healthy |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | GC | ADJ |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | GC | GC |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | HNSCC | ADJ |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | HNSCC | OSCC |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Lung | ADJ |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Lung | AIS |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Lung | IAC |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Lung | MIAC |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Lung | Precancer |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Prostate | Tumor |
| CCL21 | CCR7 | CCL21_CCR7 | CCL | Skin | ADJ |
| CCL21 | ACKR4 | CCL21_ACKR4 | CCL | Skin | ADJ |
| Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCL21 | SNV | Missense_Mutation | c.311G>A | p.Arg104Lys | p.R104K | O00585 | protein_coding | tolerated(0.68) | benign(0) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| CCL21 | SNV | Missense_Mutation | novel | c.205N>A | p.Arg69Ser | p.R69S | O00585 | protein_coding | tolerated(0.23) | possibly_damaging(0.523) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
| CCL21 | SNV | Missense_Mutation | c.116N>G | p.Lys39Arg | p.K39R | O00585 | protein_coding | tolerated(0.15) | possibly_damaging(0.655) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| CCL21 | SNV | Missense_Mutation | rs750044894 | c.199C>T | p.Arg67Cys | p.R67C | O00585 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| CCL21 | SNV | Missense_Mutation | novel | c.124N>A | p.Ala42Thr | p.A42T | O00585 | protein_coding | tolerated(0.39) | benign(0.005) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCL21 | SNV | Missense_Mutation | rs749355595 | c.175N>G | p.Ile59Val | p.I59V | O00585 | protein_coding | deleterious(0.01) | benign(0.235) | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| CCL21 | SNV | Missense_Mutation | novel | c.118N>T | p.Ile40Phe | p.I40F | O00585 | protein_coding | tolerated(0.09) | probably_damaging(0.984) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| CCL21 | SNV | Missense_Mutation | c.265N>A | p.His89Asn | p.H89N | O00585 | protein_coding | deleterious(0.01) | benign(0.113) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6366 | CCL21 | DRUGGABLE GENOME | ADENOVIRAL VECTOR | 14613584 | ||
| 6366 | CCL21 | DRUGGABLE GENOME | LT-BETA | 15632007 | ||
| 6366 | CCL21 | DRUGGABLE GENOME | HEPARIN | HEPARIN | 11286540 | |
| 6366 | CCL21 | DRUGGABLE GENOME | ANTIANGIOGENIC | 10925282 | ||
| 6366 | CCL21 | DRUGGABLE GENOME | CXC CHEMOKINES | 10737895 | ||
| 6366 | CCL21 | DRUGGABLE GENOME | IMMUNOMODULATORS | 14610196 | ||
| 6366 | CCL21 | DRUGGABLE GENOME | CHEMOKINES | 11286540,11163192,10496316,12209625,14707047,15919372,11929789,10790423,15358618,10925282,12580544 | ||
| 6366 | CCL21 | DRUGGABLE GENOME | CALDARET HYDRATE | |||
| 6366 | CCL21 | DRUGGABLE GENOME | MIP-1BETA | 10737895 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |